TABLE 1.
IC50s of all tested samples in the drug susceptibility assays
| Proteina | Duration of drug susceptibility assay (h) | No. of replication cycles (stages) | P. falciparum strain | IC50 (nM)b | 95% CI (nM) | Relative enzymatic activity (AU)e | Activity-corrected IC50 (95% CI) (nM) |
|---|---|---|---|---|---|---|---|
| Gb | 72 | 1.5 (ring-schizont- schizont | 3D7A | 1,590 | 1,197–2,112 | 1.09 | 1,733 (1,305–2,302) |
| EGb | 3D7A | >3,000c | 0 | NAd | |||
| 2.44IgG1 | 48 | 1 (schizont-schizont) | 3D7A | >25,000c | NA | NA | |
| Gb-2.44 | 3D7A | 176 | 154–202 | 1 | 176 (154–202) | ||
| Gb-H22 | 3D7A | 1,103 | 949–1,283 | 0.95 | 1,048 (902–1,219) | ||
| Gb-Ki4 | 3D7A | 1,500 | 1,180–1,905 | 0.85 | 1,275 (1,003–1,619) | ||
| Gb | 3D7A | 970 | 852–1,104 | 1.09 | 1,057 (929–1,203) | ||
| EGb-2.44 | 3D7A | >4,000c | 0 | NA | |||
| EGb-H22 | 3D7A | >4,000c | 0 | NA | |||
| EGb-Ki4 | 3D7A | >4,000c | 0 | NA | |||
| Gb-2.44 | 30 | 0.5 (ring-schizont) | 3D7A | 1,773 | 1,496–2,102 | 1 | 1,773 (1,496–2,102) |
| Gb-H22 | 3D7A | 3,668 | 2,804–4,798 | 0.95 | 3,485 (2,664–4,558) | ||
| Gb | 3D7A | 2,143 | 1,426–3,220 | 1.09 | 2,336 (1,554–3,510) | ||
| Gb-2.44 | 48 | 1 (schizont-schizont) | K1 | 386 | 306–488 | 1 | 386 (306–488) |
| Gb-H22 | K1 | 3,497 | 2,368–5,166 | 0.95 | 3,322 (2,250–4,908) | ||
| Gb-Ki4 | K1 | >2,000c | 0.85 | NA |
a
Gb, active granzyme B; EGb, inactive granzyme B with retained N-terminal protective peptide and enterokinase cleavage site; 2.44IgG1, MSP4-specific full-size chimeric antibody; Gb-2.44, MSP4-specific Gb-scFv fusion protein; Gb-H22 and Gb-Ki4, P. falciparum-unrelated Gb-scFv fusion proteins.
c
If no inhibition of parasite growth was determined at the highest applied concentration, this highest applied concentration was given.
d
NA, not applicable.
e
AU, arbitrary units.